- Home
- NEPH vs ALGS Comparison
NEPH vs ALGS Comparison
Compare NEPH & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEPH | ALGS |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 49.7M |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NEPH | ALGS |
|---|---|---|
| Price | $4.00 | $7.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $46.67 |
| AVG Volume (30 Days) | ★ 42.5K | 38.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 106.67 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $14,162,000.00 | $3,611,000.00 |
| Revenue This Year | $33.32 | N/A |
| Revenue Next Year | $12.27 | N/A |
| P/E Ratio | $40.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.40 | $3.76 |
| 52 Week High | $6.42 | $17.25 |
Technical Indicators
Market Signals| Indicator | NEPH | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 45.15 |
| Support Level | $3.48 | $6.92 |
| Resistance Level | $4.27 | $8.84 |
| Average True Range (ATR) | 0.36 | 0.55 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 60.33 | 56.21 |
Price Performance
Historical ComparisonAbout NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.